Biogen Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.26. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | SPUS | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $59.51 |
52-Week Low | $128.93 | $46.28 |
Enterprise Value | $37.20B | — |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →